

Ian E Krop

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5449237/ian-e-krop-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

112
papers

12,457
citations

49
h-index

111
g-index

119
ext. papers

15,863
ext. citations

10.7
avg, IF

6.06
L-index

#	Paper	IF	Citations
112	Trastuzumab emtansine for HER2-positive advanced breast cancer. <i>New England Journal of Medicine</i> , 2012 , 367, 1783-91	59.2	2378
111	CDK4/6 inhibition triggers anti-tumour immunity. <i>Nature</i> , 2017 , 548, 471-475	50.4	618
110	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 610-621	59.2	536
109	Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. <i>Journal of Clinical Oncology</i> , 2011 , 29, 398-405	2.2	518
108	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2018 , 4, 173-182	13.4	467
107	Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2698-704	2.2	467
106	Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 689-99	21.7	462
105	Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 134-41	59.2	455
104	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 597-609	59.2	396
103	Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. <i>Nature</i> , 2016 , 529, 413-417	50.4	363
102	Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 732-742	21.7	289
101	Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2078-99	2.2	270
100	A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3234-41	2.2	264
99	Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 743-754	21.7	244
98	Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. <i>Cancer Cell</i> , 2016 , 29, 255-269	24.3	244
97	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. <i>Journal of Clinical Oncology</i> , 2016 , 34, 542-9	2.2	242
96	Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 1229-40	3.5	200

95	Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 811-821	21.7	194
94	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2838-2847	2.2	178
93	Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1887-1896	2.2	153
92	Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. <i>Lancet Oncology, The</i> , 2019 , 20, 816-826	21.7	150
91	Current Landscape of Immunotherapy in Breast Cancer: A Review. <i>JAMA Oncology</i> , 2019 , 5, 1205-1214	13.4	143
90	Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2100-8	2.2	129
89	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2016 , 34, 945-52	2.2	121
88	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1868-1875	2.2	120
87	Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 543-553	2.2	113
86	Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. <i>Cancer Discovery</i> , 2017 , 7, 704-715	24.4	104
85	Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. <i>Cancer Discovery</i> , 2020 , 10, 688-701	24.4	104
84	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2736-2740	2.2	103
83	Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	99
82	Phase III study of tasisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.. <i>Journal of Clinical Oncology</i> , 2018 , 36, LBA1006-LBA1006	2.2	99
81	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4274-4282	2.2	92
80	The Evolving Landscape of HER2 Targeting in Breast Cancer. <i>JAMA Oncology</i> , 2015 , 1, 1154-61	13.4	81
79	Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2750-7	2.2	81
78	A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. <i>Cancer</i> , 2012 , 118, 5733-40	6.4	77

77	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. <i>Nature Medicine</i> , 2016 , 22, 723-6	50.5	76
76	Tumor Mutational Burden and Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 2565-2572	12.9	71
75	A putative role for psoriasin in breast tumor progression. <i>Cancer Research</i> , 2005 , 65, 11326-34	10.1	71
74	Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2635-40	2.2	70
73	Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 15-20	12.9	67
72	Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2303-11	2.2	61
71	A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 591-601	3.5	61
70	Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 1214-1220	13.4	61
69	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2804-2807	2.2	59
68	HIN-1, an inhibitor of cell growth, invasion, and AKT activation. <i>Cancer Research</i> , 2005 , 65, 9659-69	10.1	55
67	Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to Preoperative Trastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 3249-59	12.9	54
66	Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. <i>Cancer Cell</i> , 2014 , 26, 222-34	24.3	51
65	The ethical use of mandatory research biopsies. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 620-5	19.4	51
64	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1448-1457	2.2	50
63	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016 , 2, 29-36	13.4	48
62	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 46-54	9.7	48
61	Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 167, 731-740	4.4	48
60	Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. <i>British Journal of Cancer</i> , 2018 , 119, 1086-1093	8.7	48

59	Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1136-42	2.2	46
58	Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. <i>International Journal of Cancer</i> , 2016 , 139, 2336-42	7.5	46
57	The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. <i>Clinical Cancer Research</i> , 2019 , 25, 4644-4655	12.9	41
56	Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 5292-5304	12.9	41
55	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 4380-4387	12.9	41
54	Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. <i>Investigational New Drugs</i> , 2015 , 33, 1108-14	4.3	39
53	An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 657-72	6.2	35
52	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. <i>Nature Medicine</i> , 2020 , 26, 1280-1284	50.5	34
51	Frequent HIN-1 Promoter Methylation and Lack of Expression in Multiple Human Tumor Types. <i>Molecular Cancer Research</i> , 2004 , 2, 489-494	6.6	33
50	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 2556-2564	12.9	32
49	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). <i>Journal of Clinical Oncology</i> , 2015 , 33, 2623-31	2.2	31
48	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4184-4193	2.2	28
47	Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 1598-1605	13.4	28
46	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 714-722	7.2	26
45	Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2016 , 18, 34	8.3	26
44	SU2C phase 1b study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	26
43	A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020 , 20, 238-245	3	24
42	Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. <i>Molecular Cancer Research</i> , 2004 , 2, 489-94	6.6	24

41	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2020 , 22, 120	8.3	22
40	Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1012-1012	2.2	21
39	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2375-2385	2.2	20
38	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Focused Update Guideline Summary. <i>Journal of Oncology Practice</i> , 2017 , 13, 763-766	3.1	17
37	Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. <i>Cancer Discovery</i> , 2021 , 11, 2474-2487	24.4	17
36	Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2020 , 192, 507-520	4.4	14
35	Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 500-500	2.2	14
34	CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. <i>Nature Cancer</i> , 2021 , 2, 34-48	15.4	13
33	Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 108, 227-241	4	11
32	Genomic Characterization of Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 1105-1118	12.9	11
31	Ten years of HER2-directed therapy: still questions after all these years. <i>Breast Cancer Research and Treatment</i> , 2009 , 113, 207-9	4.4	10
30	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. <i>Clinical Breast Cancer</i> , 2020 , 20, 145-151.e2	3	10
29	Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 303-310	4.4	8
28	Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. <i>Npj Breast Cancer</i> , 2021 , 7, 77	7.8	7
27	A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 178, 121-133	4.4	4
26	FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. <i>Npj Breast Cancer</i> , 2021 , 7, 51	7.8	4
25	Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations Summary. <i>Journal of Oncology Practice</i> , 2016 , 12, 482-484	3.1	4
24	Lessons from breast cancer trials of HER2-kinase inhibitors. <i>Lancet Oncology, The</i> , 2016 , 17, 267-268	21.7	3

23	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100896	2.2	3
22	Local therapy outcomes and toxicity from the (anonymized for review) trial: A phase II randomized trial of adjuvant trastuzumab emtansine vs. paclitaxel in combination with trastuzumab in women with stage I HER2-positive breast cancer.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022 ,	4	3
21	The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer. <i>JCI Insight</i> , 2021 , 6,	9.9	3
20	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2247-2256	2.2	3
19	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. <i>Nature Communications</i> , 2021 , 12, 5563	17.4	3
18	Relationship between tumor biomarkers (BM) and efficacy in TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician's choice (TPC) in HER2-positive advanced breast cancer (BC) previously treated with trastuzumab and lapatinib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 153-153	2.2	2
17	Patient-reported outcomes (PROs) from TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician's choice (TPC) in patients with pretreated HER2-positive advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 153-153	2.2	2
16	The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 187, 155-165	4.4	2
15	Phase II Study of Taselisib in -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100424	3.6	1
14	Beyond Trastuzumab and Lapatinib: New Options for HER2-Positive Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , e2-e11	7.1	1
13	Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells.. <i>JCO Precision Oncology</i> , 2021 , 5, 896-903	3.6	1
12	Reply to J.L. Blum et al and S. Lange et al. <i>Journal of Clinical Oncology</i> , 2018 , 36, 430-431	2.2	1
11	Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer with a Focus on Breast Cancer 2013 , 179-210		1
10	Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth.. <i>Nature Biomedical Engineering</i> , 2022 ,	19	1
9	Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1+ tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. <i>Future Oncology</i> , 2021 , 17, 4665-4676	3.6	0
8	A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 183, 1147-1153	4.4	0
7	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.. <i>Npj Breast Cancer</i> , 2022 , 8, 18	7.8	0
6	Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.. <i>European Journal of Cancer</i> , 2022 , 166, 219-229	7.5	0

- 5 A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer.. *Npj Breast Cancer*, **2022**, 8, 63 7.8 ○
- 4 Targeted therapies: HER2-positive breast cancer-sifting through many good options. *Nature Reviews Clinical Oncology*, **2013**, 10, 312-3 19.4
- 3 Reply to T.J.A. Dekker. *Journal of Clinical Oncology*, **2020**, 38, 3351-3352 2.2
- 2 Reply to M. Tanaka et al. *Journal of Clinical Oncology*, **2021**, 39, 3648-3649 2.2
- 1 Managing trastuzumab-resistant breast cancer. *Clinical Advances in Hematology and Oncology*, **2009**, 7, 108-10 0.6